Top member reports
Company Report
Last edited 4 years ago
PerformanceCommunity EngagementCommunity Endorsement
ranked
#214
Performance (50m)
-15.3% pa
Followed by
156
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#ASX Announcemen1/2/21
stale
Added 4 years ago

Highlights:

• Cooperation Agreement with Terumo Blood and Cell Technologies to promote and sell both companies complementary regenerative products in Asia-Pacific.

• Terumo Blood and Cell Technologies’ products will be used to concentrate a patient’s bone marrow and mixed into Osteopore scaffolds during implantation.

• The agreement will expose Osteopore products to Terumo Blood and Cell Technologies’ extensive network of blood centres, hospitals, therapeutic clinics, researchers, and private medical practices.

View Attachment

#1/4ly Reports 29/1/21
stale
Added 4 years ago

Highlights:

• Fourth consecutive quarter of revenue growth with A$429,700 achieved for Q4 CY20.

• Osteopore achieved revenue of A$1,504,578 for the full 2020 calendar year, marking a 36% increase over CY 2019 results.

• Signed several exclusive Distribution Agreements to promote and sell Osteopore products in Australia and New Zealand, Germany and Austria, Scandinavia, and the Middle East.

• Appointed Ex-ResMed finance executive, Carl Runde, as Chief Financial Officer.

• Recently expanded manufacturing facility now fully operational.

• Cash balance of A$9.0m at 31 December 2020.

View Attachment